Newsletter

Sign up for the newsletter. We'll inform you about the progress of our projects and milestones achieved.

Learn more

Innovation in Service of Patients

InnoMedica is a Swiss pharmaceutical company specialized in drug development with innovative nano transport systems that improve patient therapy. With InnoMedica’s nanocarriers, pharmaceutical agents circulate in the bloodstream for longer and are released at the designated location in the body with precision. InnoMedica thereby addresses the challenge of an efficient biodistribution of active agents in the human body, simultaneously leading to improved efficacy and reduced side effects. First applications in oncology, neurology, and virology demonstrate the impressive versatility of this nanotechnology. Translation risks in InnoMedica’s drugs are unusually low because InnoMedica does not develop new active substances, but instead equips clinically established medicines with a biological autopilot. At InnoMedica, experienced entrepreneurs and researchers work together in order to bring these drugs to patients as expediently as possible.

 

Our Products

Delivery system with precise focus

The patent-protected drug-delivery system can be combined with a multitude of medical agents and fine-tuned according to specific requirements. This versatility enables its use in a multitude of applications.

 

Our Focus

Efficient Therapies with Fewer Side-Effects

In developing its medicines, InnoMedica focusses on the patient and his/her wish for improved health and quality of life. This means prioritizing patient benefits, as well as the real-world applicability of new drugs. Improved patient benefits primarily depend on an increase in therapeutic efficacy and a decrease in side effects. In order to reduce time to approval, InnoMedica builds its medicines on approved, best-in-class active substances.

38

patients treated with Talidox

12

patients treated with Talineuren

51

employees are working on InnoMedica’s vision

65

Mio. CHF raised

1400

shareholders are
invested in InnoMedica

Statements

Statements on Our Work

 

News

Most Recent Updates

May 2022

Parkinson trial and internationalization

NEON trial: Dose escalation completed – Parkinson’s patients want to continue treatment with Talineuren. The first …

Read more

March 2022

Stéfan Halbherr and InnoMedica receive CLINAM Award

CLINAM Award 2022 for special achievements in nanomedicine for Stéfan Halbherr and InnoMedica The Scientific Committee of …

Read more

March 2022

Update Talineuren and Capital Increase 2022

First Parkinson’s patients in the NEON study treated with Talineuren On December 14, 2021, the clinical …

Read more